Premium
New Anticoagulation Drugs for Atrial Fibrillation
Author(s) -
Potpara T S,
Lip G Y H
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.180
Subject(s) - atrial fibrillation , vitamin k antagonist , medicine , clinical pharmacology , vitamin k , stroke (engine) , warfarin , anticoagulant , anticoagulant therapy , pharmacology , intensive care medicine , mechanical engineering , engineering
Atrial fibrillation (AF) confers an increased risk of ischemic stroke or thromboembolism that is reduced by long‐term oral anticoagulant therapy. Until recently, the latter has typically been one from the vitamin K antagonist (VKA) class of drugs. Although highly effective, VKAs have limitations, and their use is challenging for both patients and clinicians. A new generation of oral anticoagulant drugs is emerging, including several drugs that appear to be viable alternatives to VKAs in AF patients. Clinical Pharmacology & Therapeutics (2011) 90 4, 502–506. doi: 10.1038/clpt.2011.180